Search

Your search keyword '"Soumerai, Jacob D."' showing total 248 results
Start Over Author "Soumerai, Jacob D."
248 results on '"Soumerai, Jacob D."'

2. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial

Author

Pagel, John M, Soumerai, Jacob D, Reddy, Nishitha, Jagadeesh, Deepa, Stathis, Anastasios, Asch, Adam, Salman, Huda, Kenkre, Vaishalee P, Iasonos, Alexia, Llorin-Sangalang, Judith, Li, Joanne, and Zelenetz, Andrew D

Published
2022
Full Text
View/download PDF

4. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study

Author

Haydu, J. Erika, Maron, Jenny S., Redd, Robert A., Gallagher, Kathleen M.E., Fischinger, Stephanie, Barnes, Jeffrey A., Hochberg, Ephraim P., Johnson, P. Connor, Takvorian, R.W., Katsis, Katelin, Portman, Daneal, Ruiters, Jade, Sechio, Sidney, Devlin, Mary, Regan, Connor, Blumenthal, Kimberly G., Banerji, Aleena, Judd, Allen D., Scorsune, Krista J., McGree, Brianne M., Sherburne, Maryanne M., Lynch, Julia M., Weitzman, James I., Lei, Matthew, Kotton, Camille N., Dighe, Anand S., Maus, Marcela V., Alter, Galit, Abramson, Jeremy S., and Soumerai, Jacob D.

Published
2022
Full Text
View/download PDF

6. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial

Author

Soumerai, Jacob D, Mato, Anthony R, Dogan, Ahmet, Seshan, Venkatraman E, Joffe, Erel, Flaherty, Kelsey, Carter, Jason, Hochberg, Ephraim, Barnes, Jeffrey A, Hamilton, Audrey M, Abramson, Jeremy S, Batlevi, Connie L, Matasar, Matthew J, Noy, Ariela, Owens, Colette N, Palomba, M Lia, Kumar, Anita, Takvorian, Tak, Ni, Ai, Choma, Morgan, Friedman, Chaya, Chadha, Puja, Simkins, Elizabeth, Ruiters, Jade, Sechio, Sidney, Portman, Daneal, Ramos, Lauren, Nolet, Natascha, Mahajan, Neena, Martignetti, Rosalba, Mi, Joanna, Scorsune, Krista, Lynch, Julia, McGree, Brianne, Hughes, Stephanie, Grieve, Clare, Roeker, Lindsey E, Thompson, Meghan, Johnson, P Connor, Roshal, Mikhail, Huang, Jane, Biondo, Juliana, Wu, Qun, Jacob, Allison, Abdel-Wahab, Omar, and Zelenetz, Andrew D

Published
2021
Full Text
View/download PDF

7. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas

Author

Soumerai, Jacob D., primary, Diefenbach, Catherine S., additional, Jagadeesh, Deepa, additional, Asch, Adam, additional, Kumar, Abhijeet, additional, Tsai, Michaela L., additional, Jandl, Thomas A., additional, Lossos, Izidore S., additional, Kenkre, Vaishalee P., additional, Awan, Farrukh, additional, Novotny, William, additional, Huang, Jane, additional, Miao, Lu, additional, Rajagopalan, Prabhu, additional, Ghalie, Richard G., additional, and Zelenetz, Andrew D., additional

Published
2024
Full Text
View/download PDF

8. Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP

Author

Nemec, Ronald, primary, Scherrer-Crosbie, Marielle, additional, Abramson, Jeremy S., additional, Redd, Robert, additional, Gilman, Hannah K., additional, Ho, Terry, additional, Wu, Jessica, additional, Heemelaar, Julius, additional, Neuberg, Donna, additional, Hochberg, Ephraim P., additional, Barnes, Jeffrey A., additional, Armand, Philippe, additional, Jacobsen, Eric D., additional, Jacobson, Caron A., additional, Kim, Austin I., additional, Friedman, Robb S., additional, LaCasce, Ann S., additional, Neilan, Tomas G., additional, and Soumerai, Jacob D., additional

Published
2024
Full Text
View/download PDF

9. Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Author

Lei, Matthew M., Sorial, Mark N., Lou, Uvette, Yu, Michelle, Medrano, Andrea, Ford, Josie, Nemec, Ronald A., Abramson, Jeremy S., and Soumerai, Jacob D.

Subjects
CHRONIC lymphocytic leukemia, LYMPHOCYTIC leukemia, VENETOCLAX, LYMPHOMAS, PROGRESSION-free survival
Abstract

Venetoclax-obinutuzumab (Ven-O) is frequently administered off-label in relapsed/refractory (r/r) CLL/SLL where venetoclax-rituximab is the approved regimen. We conducted this retrospective, real-world study to evaluate Ven-O in r/r CLL/SLL. Between 7/2019 and 6/2022, 40 patients with r/r CLL/SLL on Ven-O were included. The median age was 72, 28.2% had TP53 mutation and/or 17p deletion, median number of prior therapies was 1 (range, 1–6), and 55% had prior BTK inhibitor exposure. The overall response rate was 90% (complete response [CR] or CR with incomplete marrow recovery in 27.5% and partial response in 62.5%) of patients, and the 2-year progression-free survival was 81.2% (95% CI, 69.5–94.8). Therapy was well tolerated. No laboratory or clinical TLS occurred with venetoclax (Howard criteria). One (3%) patient experienced laboratory TLS with obinutuzumab initiation. In summary, this retrospective cohort study demonstrated that Ven-O achieves frequent, durable responses and can be safely administered in r/r CLL/SLL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. CTIM-38. NEUROTOXICITY AND MANAGEMENT OF PRIMARY AND SECONDARY CNS LYMPHOMA AFTER ADOPTIVE IMMUNOTHERAPY WITH CD19-DIRECTED CAR T-CELLS

Author

Karschnia, Philipp, primary, Arrillaga-Romany, Isabel, additional, Eichler, April, additional, Forst, Deborah, additional, Gerstner, Elizabeth, additional, Jordan, Justin T, additional, Ly, Ina, additional, Plotkin, Scott R, additional, Wang, Nancy, additional, Martinez-Lage, Maria, additional, Winter, Sebastian F, additional, Tonn, Joerg-Christian, additional, Rejeski, Kai, additional, von Baumgarten, Louisa, additional, Cahill, Daniel, additional, Nahed, Brian V, additional, Shankar, Ganesh M, additional, Abramson, Jeremy S, additional, Barnes, Jeffrey A, additional, El-Jawahri, Areej, additional, Hochberg, Ephraim P, additional, Johnson, P Connor, additional, Soumerai, Jacob D, additional, Takvorian, Ronald W, additional, Chen, Yi-Bin, additional, Frigault, Matthew J, additional, and Dietrich, Jorg, additional

Published
2023
Full Text
View/download PDF

11. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations

Author

Soumerai, Jacob D, Ni, Ai, Darif, Mohamed, Londhe, Anil, Xing, Guan, Mun, Yong, Kay, Neil E, Shanafelt, Tait D, Rabe, Kari G, Byrd, John C, Chanan-Khan, Asher A, Furman, Richard R, Hillmen, Peter, Jones, Jeffrey, Seymour, John F, Sharman, Jeffrey P, Ferrante, Lucille, Mobasher, Mehrdad, Stark, Thomas, Reddy, Vijay, Dreiling, Lyndah K, Bhargava, Pankaj, Howes, Angela, James, Danelle F, and Zelenetz, Andrew D

Published
2019
Full Text
View/download PDF

13. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction

Author

Neilan, Tomas G., primary, Quinaglia, Thiago, additional, Onoue, Takeshi, additional, Mahmood, Syed S., additional, Drobni, Zsofia D., additional, Gilman, Hannah K., additional, Smith, Amanda, additional, Heemelaar, Julius C., additional, Brahmbhatt, Priya, additional, Ho, Jor Sam, additional, Sama, Supraja, additional, Svoboda, Jakub, additional, Neuberg, Donna S., additional, Abramson, Jeremy S., additional, Hochberg, Ephraim P., additional, Barnes, Jefferey A., additional, Armand, Philippe, additional, Jacobsen, Eric D., additional, Jacobson, Caron A., additional, Kim, Austin I., additional, Soumerai, Jacob D., additional, Han, Yuchi, additional, Friedman, Robb S., additional, Lacasce, Ann S., additional, Ky, Bonnie, additional, Landsburg, Dan, additional, Nasta, Sunita, additional, Kwong, Raymond Y., additional, Jerosch-Herold, Michael, additional, Redd, Robert A., additional, Hua, Lanqi, additional, Januzzi, James L., additional, Asnani, Aarti, additional, Mousavi, Negareh, additional, and Scherrer-Crosbie, Marielle, additional

Published
2023
Full Text
View/download PDF

15. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

Author

Batlevi, Connie L., Sha, Fushen, Alperovich, Anna, Ni, Ai, Smith, Katy, Ying, Zhitao, Soumerai, Jacob D., Caron, Philip C., Falchi, Lorenzo, Hamilton, Audrey, Hamlin, Paul A., Horwitz, Steven M., Joffe, Erel, Kumar, Anita, Matasar, Matthew J., Moskowitz, Alison J., Moskowitz, Craig H., Noy, Ariela, Owens, Colette, Palomba, Lia M., Straus, David, von Keudell, Gottfried, Zelenetz, Andrew D., Seshan, Venkatraman E., and Younes, Anas

Published
2020
Full Text
View/download PDF

16. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphoma.

Author

Ababneh, Hazim S., Ng, Andrea K., Abramson, Jeremy S., Soumerai, Jacob D., Takvorian, Ronald W., Frigault, Matthew J., and Patel, Chirayu G.

Subjects
POSITRON emission tomography computed tomography, CHIMERIC antigen receptors, CUTANEOUS T-cell lymphoma, T cells, CYTOKINE release syndrome, DIFFUSE large B-cell lymphomas, PROGNOSIS
Abstract

CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy has revolutionized treatment for patients with relapsed/refractory large B‐cell lymphoma (LBCL). However, data available concerning the impact of the prognostic value of quantitative 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography (FDG PET/CT) parameters on the CAR T‐related outcomes and toxicities are limited. Therefore, we aimed to evaluate the predictive value of pre‐ and post‐CAR T metabolic parameters on survival and toxicities following CAR T‐cell therapy. Fifty‐nine patients with PET/CT scans done pre‐and post‐CAR T infusion were retrospectively identified and analyzed in a single institution database of LBCL patients treated with commercial CD19‐targeted CAR T‐cell therapy. The median follow‐up was 10.7 months [interquartile range (IQR): 2.6–25.5 months]. The overall response (complete response‐CR and partial response) and CR rates post‐CAR T were 76% (n = 45) and 53% (n = 31), respectively. On univariate analysis, low pre‐CAR T total lesion glycolysis (TLG) and metabolic tumor volume (MTV) predicted improved overall response post‐CAR T (OR = 4.7, p = 0.01, OR = 9.5, p = 0.03, respectively) and CR post‐CAR T (OR = 12.4, p = 0.0004, OR = 10.9, p = 0.0001, respectively). High TLG pre‐CAR T was correlated with cytokine release syndrome (CRS, OR = 3.25, p = 0.04). High MTV pre‐CAR T was correlated with developing immune effector cell neurotoxicity syndrome (ICANS) events (OR = 4.3, p = 0.01), and high SUV pre‐CAR T was associated with grade 3–4 neurological events (OR = 12, p = 0.01). High MTV/TLG/SUVmax post‐CAR T were significantly associated with inferior Overall survival (OS). On multivariate analysis, high TLG pre‐CAR T (HR = 2.4, p = 0.03), age ≥60 (HR = 2.7, p = 0.03), and bulky disease (≥5 cm) at the time of apheresis (HR = 2.5, p = 0.02) were identified to be independent prognostic factors for inferior PFS. High MTV post‐CAR T was identified as the most prognostic factor associated with inferior OS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes.

Author

Redd, Robert A., Ford, Josie, Lei, Matthew, Abramson, Jeremy S., and Soumerai, Jacob D.

Subjects
BRUTON tyrosine kinase, ATRIAL fibrillation
Abstract

BTK inhibitors (BTKi) are highly effective in B-cell malignancies. Acalabrutinib and zanubrutinib have exhibited favorable safety profiles when compared with ibrutinib. We identified all published/ presented randomized trials comparing a second-generation BTKi with ibrutinib and reconstructed individual patient-level, censored time-to-event data for adverse events to evaluate the impact of second-generation BTKi on safety outcomes including atrial fibrillation/flutter [AF], hypertension, bleeding, diarrhea, and infection. 1386 pts from ELEVATE-RR (n=533), ALPINE (n=652), and ASPEN (n=201) trials were included in the analyses. Acalabrutinib or zanubrutinib were associated with significant reductions in cumulative event rates of AF (HR 0.28, 95% CI 0.18–0.42, p<0.001), bleeding (HR 0.65, 95% CI 0.52–0.81, p<0.001), diarrhea (HR 0.61, 95% CI 0.47–0.78, p<0.001), hypertension (HR 0.40, 95% CI 0.27–0.61, p<0.001), and infections (HR 0.83, 95% CI 0.70-0.98, p=0.032). In summary, zanubrutinib and acalabrutinib have a favorable safety profile among pts with r/r B-cell malignancies. These data support use of acalabrutinib or zanubrutinib as preferred BTK inhibitors for approved indications. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Supplementary Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Author

Roeker, Lindsey E., primary, Feldman, Tatyana A., primary, Soumerai, Jacob D., primary, Falco, Victoria, primary, Panton, Gail, primary, Dorsey, Colleen, primary, Zelenetz, Andrew D., primary, Falchi, Lorenzo, primary, Park, Jae H., primary, Straus, David J., primary, Pena Velasquez, Camila, primary, Lebowitz, Sonia, primary, Fox, Yehudit, primary, Battiato, Kristen, primary, Laudati, Carissa, primary, Thompson, Meghan C., primary, McCarthy, Elizabeth, primary, Kdiry, Sabrina, primary, Martignetti, Rosalba, primary, Turpuseema, Teja, primary, Purdom, Michelle, primary, Paskalis, Dana, primary, Miskin, Hari P., primary, Sportelli, Peter, primary, Leslie, Lori A., primary, and Mato, Anthony R., primary

Published
2023
Full Text
View/download PDF

19. Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Author

Roeker, Lindsey E., primary, Feldman, Tatyana A., primary, Soumerai, Jacob D., primary, Falco, Victoria, primary, Panton, Gail, primary, Dorsey, Colleen, primary, Zelenetz, Andrew D., primary, Falchi, Lorenzo, primary, Park, Jae H., primary, Straus, David J., primary, Pena Velasquez, Camila, primary, Lebowitz, Sonia, primary, Fox, Yehudit, primary, Battiato, Kristen, primary, Laudati, Carissa, primary, Thompson, Meghan C., primary, McCarthy, Elizabeth, primary, Kdiry, Sabrina, primary, Martignetti, Rosalba, primary, Turpuseema, Teja, primary, Purdom, Michelle, primary, Paskalis, Dana, primary, Miskin, Hari P., primary, Sportelli, Peter, primary, Leslie, Lori A., primary, and Mato, Anthony R., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure Legends from The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

Author

Soumerai, Jacob D., primary, Zelenetz, Andrew D., primary, Moskowitz, Craig H., primary, Palomba, M. Lia, primary, Hamlin, Paul A., primary, Noy, Ariela, primary, Straus, David J., primary, Moskowitz, Alison J., primary, Younes, Anas, primary, Matasar, Matthew J., primary, Horwitz, Steven M., primary, Portlock, Carol S., primary, Konner, Jason A., primary, Gounder, Mrinal M., primary, Hyman, David M., primary, Voss, Martin H., primary, Fury, Matthew G., primary, Gajria, Devika, primary, Carvajal, Richard D., primary, Ho, Alan L., primary, Beumer, Jan H., primary, Kiesel, Brian, primary, Zhang, Zhigang, primary, Chen, Alice, primary, Little, Richard F., primary, Jarjies, Christine, primary, Dang, Thu O., primary, France, Fallon, primary, Mishra, Nishant, primary, and Gerecitano, John F., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure S1 from The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

Author

Soumerai, Jacob D., primary, Zelenetz, Andrew D., primary, Moskowitz, Craig H., primary, Palomba, M. Lia, primary, Hamlin, Paul A., primary, Noy, Ariela, primary, Straus, David J., primary, Moskowitz, Alison J., primary, Younes, Anas, primary, Matasar, Matthew J., primary, Horwitz, Steven M., primary, Portlock, Carol S., primary, Konner, Jason A., primary, Gounder, Mrinal M., primary, Hyman, David M., primary, Voss, Martin H., primary, Fury, Matthew G., primary, Gajria, Devika, primary, Carvajal, Richard D., primary, Ho, Alan L., primary, Beumer, Jan H., primary, Kiesel, Brian, primary, Zhang, Zhigang, primary, Chen, Alice, primary, Little, Richard F., primary, Jarjies, Christine, primary, Dang, Thu O., primary, France, Fallon, primary, Mishra, Nishant, primary, and Gerecitano, John F., primary

Published
2023
Full Text
View/download PDF

22. Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection

Author

Bantilan, Kurt S., primary, Kay, Neil E., additional, Parikh, Sameer A., additional, Rabe, Kari G., additional, Call, Timothy G., additional, Leis, Jose F., additional, Ding, Wei, additional, Slager, Susan L., additional, Soumerai, Jacob D., additional, Roeker, Lindsey E., additional, Mato, Anthony, additional, and Zelenetz, Andrew D., additional

Published
2022
Full Text
View/download PDF

23. Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Author

Ryan, Christine E., primary, Crombie, Jennifer L., additional, Tyekucheva, Svitlana, additional, McDonough, Mikaela M., additional, Montegaard, Josie S., additional, Kim, Austin I., additional, Soumerai, Jacob D., additional, Alencar, Alvaro J., additional, Bhandari, Shruti, additional, Fisher, David C., additional, Brown, Jennifer R., additional, and Davids, Matthew S., additional

Published
2022
Full Text
View/download PDF

24. A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Author

Soumerai, Jacob D., primary, Lasica, Masa, additional, Opat, Stephen, additional, Cheah, Chan Y., additional, Chan, Henry, additional, Verner, Emma, additional, González Barca, Eva, additional, Tedeschi, Alessandra, additional, Hilger, James, additional, Fang, Yiqian, additional, Simpson, David, additional, and Tam, Constantine S., additional

Published
2022
Full Text
View/download PDF

25. Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Author

Soumerai, Jacob D., primary, Diefenbach, Catherine S., additional, Samaniego, Felipe, additional, Kumar, Abhijeet, additional, Tsai, Michaela L., additional, Asch, Adam S., additional, Jagadeesh, Deepa, additional, Kenkre, Vaishalee P., additional, Lossos, Izidore S., additional, Salman, Huda, additional, Awan, Farrukh T., additional, Miao, Lu, additional, Ghalie, Richard G., additional, and Zelenetz, Andrew D., additional

Published
2022
Full Text
View/download PDF

26. Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma

Author

Soumerai, Jacob D., primary, Rosenthal, Allison, additional, Harkins, Shannon, additional, Duffy, Jessica, additional, Mecca, Carmen, additional, Wang, Yingbing, additional, Grewal, Ravinder K., additional, El-Jawahri, Areej R., additional, Liu, Huiyun, additional, Menard, Cedric, additional, Dogan, Ahmet, additional, Yang, Lei, additional, Rimsza, Lisa M., additional, Bantilan, Kurt, additional, Martin, Haley, additional, Lei, Matthew, additional, Mohr, Sydney, additional, Kurilovich, Anna, additional, Kudryashova, Olga, additional, Postovalova, Ekaterina, additional, Nardi, Valentina, additional, Abramson, Jeremy S., additional, Chiarle, Roberto, additional, Zelenetz, Andrew D., additional, and Louissaint, Abner, additional

Published
2022
Full Text
View/download PDF

27. Poster: CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data

Author

Soumerai, Jacob D., primary, Opat, Stephen, additional, Cheah, Chan Y., additional, Lasica, Masa, additional, Verner, Emma, additional, Browett, Peter J., additional, Chan, Henry, additional, Barca, Eva González, additional, Hilger, James, additional, Fang, Yiqian, additional, Simpson, David, additional, and Tam, Constantine S., additional

Published
2022
Full Text
View/download PDF

29. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach

Author

Roeker, Lindsey E., Feldman, Tatyana A., Soumerai, Jacob D., Falco, Victoria, Panton, Gail, Dorsey, Colleen, Zelenetz, Andrew D., Falchi, Lorenzo, Park, Jae H., Straus, David J., Velasquez, Camila Pena, Lebowitz, Sonia, Fox, Yehudit, Battiato, Kristen, Laudati, Carissa, Thompson, Meghan C., McCarthy, Elizabeth, Kdiry, Sabrina, Martignetti, Rosalba, Turpuseema, Teja, Purdom, Michelle, Paskalis, Dana, Miskin, Hari P., Sportelli, Peter, Leslie, Lori A., and Mato, Anthony R.

Subjects
Neoplasm, Residual, Piperidines, Adenine, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humans, Heterocyclic Compounds, 4 or More Rings, Leukemia, Lymphocytic, Chronic, B-Cell, Article
Abstract

Ibrutinib has transformed the management of chronic lymphocytic leukemia (CLL), though its use is limited by toxicity and resistance. In this study, we utilized an "add on" approach for patients who had been treated with ibrutinib in the front-line or relapsed/refractory settings with detectable MRD. Umbralisib and ublituximab (U2) were added on to ibrutinib, patients were treated until achieving undetectable-MRD (U-MRD), and then they entered a period of treatment-free observation (TFO).Patients were eligible if they received ibrutinib in any line of therapy for at least 6 months and had detectable MRD (flow cytometry,1 cell in 10-4 cutoff for U-MRD). U2 was added to ibrutinib, and patients were monitored serially for MRD. Once U-MRD was achieved or a total of 24 cycles were administered, patients entered a period of TFO. The primary study objective was rate of U-MRD. Secondary endpoints included safety and durability of clinical benefit after treatment discontinuation.Twenty-eight patients were enrolled of whom 27 were evaluable for efficacy. Patients received ibrutinib for a median of 21 months (range 7-67) prior to study enrollment. Fourteen patients (52%) have achieved U-MRD per protocol whereas 78% had at least one U-MRD evaluation. Seventeen patients (63%) have entered TFO after a median of 6.4 months on triplet therapy. Progression-free survival at 12 months was estimated at 95%. Grade ≥3 adverse events were hypertension 7%, diarrhea 4%, and increased ALT/AST 4%.This triplet approach utilizes the addition of U2 to ibrutinib as an MRD-driven time-limited therapy. This therapy was well tolerated and effective. TFO following this therapy appears durable in ongoing follow-up.

Published
2022

30. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Author

Roeker, Lindsey E., primary, Feldman, Tatyana A., additional, Soumerai, Jacob D., additional, Falco, Victoria, additional, Panton, Gail, additional, Dorsey, Colleen, additional, Zelenetz, Andrew D., additional, Falchi, Lorenzo, additional, Park, Jae H., additional, Straus, David J., additional, Pena Velasquez, Camila, additional, Lebowitz, Sonia, additional, Fox, Yehudit, additional, Battiato, Kristen, additional, Laudati, Carissa, additional, Thompson, Meghan C., additional, McCarthy, Elizabeth, additional, Kdiry, Sabrina, additional, Martignetti, Rosalba, additional, Turpuseema, Teja, additional, Purdom, Michelle, additional, Paskalis, Dana, additional, Miskin, Hari P., additional, Sportelli, Peter, additional, Leslie, Lori A., additional, and Mato, Anthony R., additional

Published
2022
Full Text
View/download PDF

32. Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection.

Author

Bantilan, Kurt S., Kay, Neil E., Parikh, Sameer A., Rabe, Kari G., Call, Timothy G., Leis, Jose F., Ding, Wei, Slager, Susan L., Soumerai, Jacob D., Roeker, Lindsey E., Mato, Anthony, and Zelenetz, Andrew D.

Subjects
CHRONIC lymphocytic leukemia, OVERALL survival, DISEASE risk factors, FOLLICULAR lymphoma, CHRONIC leukemia, PROGNOSTIC models
Abstract

Targeted therapies have largely replaced chemoimmunotherapy (CIT) in first-line treatment of chronic lymphocytic leukemia (CLL). We aimed to develop a prognostic model to determine who would benefit from first-line CIT vs target therapy. In follicular lymphoma, time from diagnosis to second treatment (TT2T) correlates better with overall survival (OS) than time from diagnosis to first treatment (TT1T). We hypothesized that TT2T is a potential surrogate for OS in CLL. In a model-building cohort (n = 298), we evaluated potential predictors for TT2T and derived a risk score, which we validated in an external cohort (n = 1141). Our data demonstrated that TT2T and OS were more strongly correlated than TT1T and OS. Our risk score model consisted of three predictors (unmutated IGHV, β2-microglobulin >297 nmol/L, and Rai stage I–IV), and was prognostic for TT2T and OS. TT2T is a promising surrogate for OS in CLL, but further validation is needed to establish this association. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)

Author

Kumar, Anita, primary, Soumerai, Jacob D., additional, Abramson, Jeremy S., additional, Batlevi, Connie Lee, additional, Chadha, Puja, additional, Dogan, Ahmet, additional, Falchi, Lorenzo, additional, Flaherty, Kelsey, additional, Friedman, Chaya, additional, Grieve, Clare, additional, Ho, Caleb, additional, Johnson, P. Connor, additional, Joseph, Ashlee, additional, Khan, Niloufer, additional, Mi, Joanna, additional, Martignetti, Rosalba, additional, Matasar, Matthew J., additional, Owens, Colette, additional, Ruiters, Jade, additional, Sechio, Sidney, additional, Seshan, Venkatraman, additional, Simkins, Elizabeth, additional, Abdel-Wahab, Omar, additional, and Zelenetz, Andrew D., additional

Published
2021
Full Text
View/download PDF

36. Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

Author

Soumerai, Jacob D., primary, Mato, Anthony R., additional, Dogan, Ahmet, additional, Seshan, Venkatraman, additional, Joffe, Erel, additional, Flaherty, Kelsey, additional, Carter, Jason, additional, Hochberg, Ephraim P, additional, Barnes, Jeffrey A, additional, Hamilton, Audrey, additional, Abramson, Jeremy S., additional, Batlevi, Connie Lee, additional, Matasar, Matthew J., additional, Noy, Ariela, additional, Owens, Colette, additional, Palomba, M. Lia, additional, Kumar, Anita, additional, Takvorian, Tak, additional, Ni, Ai, additional, Choma, Morgan, additional, Friedman, Chaya, additional, Chadha, Puja, additional, Simkins, Elizabeth, additional, Ruiters, Jade, additional, Sechio, Sidney, additional, Portman, Daneal, additional, Nolet, Natascha, additional, Mahajan, Neena, additional, Martignetti, Rosalba, additional, Mi, Joanna, additional, Scorsune, Krista J, additional, Lynch, Julia M, additional, McGree, Brianne, additional, Hughes, Stephanie Y, additional, Grieve, Clare, additional, Roeker, Lindsey E., additional, Thompson, Meghan C., additional, Johnson, P. Connor, additional, Roshal, Mikhail, additional, Huang, Jane, additional, Biondo, Juliana M.L., additional, Wu, Jenny Qun, additional, Jacob, Allison P., additional, Abdel-Wahab, Omar, additional, and Zelenetz, Andrew D., additional

Published
2021
Full Text
View/download PDF

37. Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib

Author

Tam, Constantine S., primary, Verner, Emma, additional, Lasica, Masa, additional, Arbelaez, Alejandro, additional, Browett, Peter J., additional, Soumerai, Jacob D., additional, Hilger, James, additional, Fang, Yiqian, additional, Huang, Jane, additional, Simpson, David, additional, Opat, Stephen, additional, and Cheah, Chan Yoon Y., additional

Published
2021
Full Text
View/download PDF

39. CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia

Author

Ho, Allen W., Hatjiharissi, Evdoxia, Ciccarelli, Bryan T., Branagan, Andrew R., Hunter, Zachary R., Leleu, Xavier, Tournilhac, Olivier, Xu, Lian, O'Connor, Kelly, Manning, Robert J., Santos, Daniel Ditzel, Chemaly, Mariana, Patterson, Christopher J., Soumerai, Jacob D., Munshi, Nikhil C., McEarchern, Julie A., Law, Che-Leung, Grewal, Iqbal S., and Treon, Steven P.

Published
2008
Full Text
View/download PDF

40. Thalidomide and rituximab in Waldenstrom macroglobulinemia

Author

Treon, Steven P., Soumerai, Jacob D., Branagan, Andrew R., Hunter, Zachary R., Patterson, Christopher J., Ioakimidis, Leukothea, Briccetti, Frederick M., Pasmantier, Mark, Zimbler, Harvey, Cooper, Robert B., Moore, Maria, Hill, John, II, Rauch, Alan, Garbo, Lawrence, Chu, Luis, Chua, Cynthia, Nantel, Stephen H., Lovett, David R., Boedeker, Hans, Sonneborn, Henry, Howard, John, Musto, Paul, Ciccarelli, Bryan T., Hatjiharissi, Evdoxia, and Anderson, Kenneth C.

Published
2008
Full Text
View/download PDF

41. Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

Author

Crombie, Jennifer L., primary, Tyekucheva, Svitlana, additional, Wang, Zixu, additional, Savell, Alexandra, additional, Brennan, Lisa, additional, Lowney, Jessica, additional, Francoeur, Karen, additional, Montegaard, Josie, additional, Kim, Austin I., additional, Soumerai, Jacob D., additional, Arnason, Jon E., additional, Cruz, Allan Louie, additional, Berg, Sigrid, additional, Fisher, David C., additional, Brown, Jennifer R, additional, and Davids, Matthew S., additional

Published
2020
Full Text
View/download PDF

42. Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients

Author

Siddiqi, Tanya, primary, Soumerai, Jacob D., additional, Dorritie, Kathleen A., additional, Stephens, Deborah M., additional, Riedell, Peter A., additional, Arnason, Jon E., additional, Kipps, Thomas J., additional, Gillenwater, Heidi H., additional, Gong, Lucy, additional, Yang, Lin, additional, Ogasawara, Ken, additional, and Wierda, William G., additional

Published
2020
Full Text
View/download PDF

43. Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Author

Thompson, Meghan C., primary, Davids, Matthew S., additional, Jain, Nitin, additional, Soumerai, Jacob D., additional, Ramakrishnan Geethakumari, Praveen, additional, Gubits, Amy, additional, Hickman, Denice, additional, Wennborg, Anders, additional, Attar, Eyal C., additional, Abdel-Wahab, Omar, additional, and Mato, Anthony R., additional

Published
2020
Full Text
View/download PDF

44. Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

Author

Soumerai, Jacob D., primary, Ni, Andy, additional, Alperovich, Anna, additional, Batlevi, Connie, additional, Bantilan, Kurt S., additional, Fischer, Thais, additional, Copeland, Amanda R., additional, Smith, Katy, additional, Ying, Zhitao, additional, Younes, Anas, additional, and Zelenetz, Andrew D., additional

Published
2020
Full Text
View/download PDF

46. Tolerability and durable respones of the PI3Kδ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies.

Author

Zelenetz, Andrew David, primary, Reddy, Nishitha, additional, Jagadeesh, Deepa, additional, Stathis, Anastasios, additional, Salman, Huda S., additional, Soumerai, Jacob D., additional, Kenkre, Vaishalee Padgaonkar, additional, Asch, Adam Steven, additional, Llorin-Sangalang, Judith, additional, Li, Joanne, additional, Gorbatchevsky, Igor, additional, and Pagel, John M., additional

Published
2020
Full Text
View/download PDF

49. Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Author

Siddiqi, Tanya, primary, Soumerai, Jacob D., primary, Dorritie, Kathleen A., primary, Stephens, Deborah M., primary, Riedell, Peter A., primary, Arnason, Jon E., primary, Kipps, Thomas J., primary, Gillenwater, Heidi H., primary, Gong, Lucy, primary, Dubovsky, Jason A., primary, Rytlewski, Julie, primary, Yang, Lin, primary, and Wierda, William G., primary

Published
2019
Full Text
View/download PDF

50. Novel Agents in the Treatment of Waldenströmʼs Macroglobulinemia

Author

Treon, Steven P., Hatjiharissi, Evdoxia, Leleu, Xavier, Moreau, Anne-Sophie, Roccaro, Aldo, Hunter, Zachary R., Soumerai, Jacob D., Ciccarelli, Bryan, Xu, Lian, Sacco, Antonio, Ngo, Hai T., Jia, Xiaoying, Yang, Cao, Adamia, Sophia, Branagan, Andrew R., Ho, Allen W., Santos, Daniel D., Tournilhac, Olivier, Manning, Robert J., Leduc, Renee, OʼConnor, Kelly, Nelson, Marybeth, Patterson, Christopher J., and Ghobrial, Irene

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results